Table 2 Shows the distribution of number of IVI, mean monthly ophthalmologic and total cost of the different treatment groups. Note that these are unadjusted values
From: Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
Therapy | # Eyes (patients) | Mean # IVI (sda) | Ophthalmologic costs per months [CHF] (sda) | Total costs per months [CHF] (sda) |
|---|---|---|---|---|
Only ranibizumab | 182 (144) | 4.3 (2.3) | 1063.9 (549.3) | 2060.5 (1274.4) |
Only aflibercept | 63 (52) | 5.1 (2.5) | 1238.8 (735.6) | 2641.5 (1912.3) |
Switching from ranibizumab to aflibercept prior study | 160 (128) | 5.9 (2.7) | 1336.1 (742.2) | 2486.8 (1702.0) |
Switching from ranibizumab to aflibercept during study | 45 (36) | 6.9 (2.4) | 1337.1 (443.1) | 2408.5 (1133.6) |
Miscellaneousb | 38 (34) | 6.6 (3.0) | 1470.8 (770.5) | 2404.5 (1141.9) |